Original Report

Beneficial effects of animal-assisted visits on quality of life during multimodal radiation-chemotherapy regimens


 

Objective To test the efficacy of AAVs in improving the quality of life in patients with head and neck cancer receiving combined chemotherapy-radiation therapy.
Methods 42 patients consented to daily AAVs during the time they received therapy for head and neck cancer. The Functional Assessment of Cancer Therapy-General Scale (FACT-G) was administered at baseline, week 3, and week 7 (at the end of therapy), and the Satisfaction With The AAV Intervention instrument, an 18-item scale adapted from the Pet Attitude Scale.
Results 37 patients completed at least baseline and 1 follow-up assessment for a single group analysis of change over time. Means for FACT-G subscales showed significant declines in Physical Well-Being (PWB, P < .001) and Functional Well-Being (FWB, P = .003). In contrast, Social Well-Being increased (SWB, P = .03). Controlling for declines in PWB at each time point, increases in Emotional Well-Being (EWB) were also significant (P = .004).
Limitations Scheduling and patient preference prevented conducting a randomized trial.
Conclusion FACT-G analysis showed significant increase in SWB and EWB despite high symptom burden and clinically evident and expected declines in PWB and FWB. Mean scores for satisfaction related to psychological symptoms, liking animals/pets, and contact with animals were consistently higher than neutral score or Unsure (all P < .001). Satisfaction related to physical symptoms was not significantly different from neutral. Though self-selected for an affinity to pets, patients endorsed a high level of satisfaction, which supports the usefulness of the intervention.
Funding Grant from the Good Dog Foundation and Pfizer Animal Health (now Zoetis Animal Health)

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Enhanced thyroid cancer guidelines expected in 2015
MDedge Hematology and Oncology
A wonderful life
MDedge Hematology and Oncology
Impact of aprepitant on emesis control, dose intensity, and recurrence-free survival in a population-based cohort of head and neck cancer patients receiving high-dose cisplatin chemotherapy
MDedge Hematology and Oncology
Total thyroidectomy more likely with younger thyroid cancer patients
MDedge Hematology and Oncology
High failure rate seen with limited parathyroidectomy in patients with MEN-1
MDedge Hematology and Oncology
AHRQ releases update on radiotherapy for head and neck cancer
MDedge Hematology and Oncology
HIM Study: Prevalent HVP-16 infections tend to persist
MDedge Hematology and Oncology
Postdiagnosis imaging increasing for patients with all stages of thyroid cancer
MDedge Hematology and Oncology
Sunitinib elicits “exceptional” response in refractory thymic carcinoma
MDedge Hematology and Oncology
Study aims to determine prognostic factors for subset of thyroid cancer patients
MDedge Hematology and Oncology